510(k) for Radionics' NeuroMap system:
This article was originally published in Clinica
The FDA has cleared Radionics' NeuroMap system for functional neurosurgery. It is designed to treat patients with movement disorders, in particular Parkinson's disease, by allowing doctors to precisely locate brain structures such as the pallidum and thalamus. The system analyses electrical signals in the brain to target these structures before treatment is performed. NeuroMap forms part of the NeuroPlan package developed by the Burlington, Massachusetts-based company.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.